HDAC Inhibitor LBH589 Suppresses the Proliferation but Enhances the Antileukemic Effect of Human γδT Cells
γδT cells have potent effects on hematological malignancies, and their functions can be regulated by anti-tumor agents. Histone deacetylase inhibitors (HDACis) not only have antileukemic activity on leukemia but also affect immune cells during therapeutic application. In this in vitro study, we show...
Main Authors: | Ying He, Lin Xu, Jingjing Feng, Kangni Wu, Yanmin Zhao, He Huang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-09-01
|
Series: | Molecular Therapy: Oncolytics |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2372770520301200 |
Similar Items
-
Design and synthesis of potential ribonucleotide reductase enzyme (RNR) inhibitors as antileukemic and/or antiviral 2′-deoxymethylene nucleosides
by: Khairia M. Youssef, et al.
Published: (2015-12-01) -
A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma
by: Nageatte Ibrahim, et al.
Published: (2016-11-01) -
Einfluss und Wirkung des HDAC-Inhibitors LBH589 auf Proliferation und Differenzierung der kolorektalen Karzinomzelllinien SW480 und SW620
by: Eller, David Michael
Published: (2011) -
HDAC Inhibitors: Therapeutic Potential in Fibrosis-Associated Human Diseases
by: Somy Yoon, et al.
Published: (2019-03-01) -
The efficacy of HDAC inhibitors in neoplasm treatment
by: Dominika Psiuk, et al.
Published: (2020-08-01)